New Cancer Vaccine Implant From Harvard Reprograms our Cells
A Harvard-developed implantable cancer vaccination has shown promising results on mice. Researchers are now testing it for a human clinical trial. This article was originally published on LongevityFacts. Brady Hartman is the author.
The Wyss Institute at Harvard is testing an implantable cancer vaccine on patients. This new immunotherapy holds promise for treating a variety of cancers, including melanoma and auto-immune diseases. The aspirin sized implant is made from a polymer matrix containing growth factor and tissue samples taken from the patient’s tumors. This trains the patient’s immune to seek out and destroy cancerous cells.
Harvard’s cancer vaccination is nearing the end of its clinical testing and will be available four or five years earlier than Stanford’s 97% cure rate vaccine.
Source:
New Cancer Vaccine Implant from Harvard Reprograms Our Cells
